Zura Bio Limited (NASDAQ: ZURA) — Perfil da empresa, notícias e dados financeiros
Zura Bio is a clinical-stage biotech company developing novel medicines for immune and inflammatory disorders.
Zura Bio Limited
Zura Bio (NASDAQ:ZURA) is a clinical-stage biotechnology company focused on developing innovative medicines for immune and inflammatory disorders. They currently have three assets in Phase 2 ready stage, targeting conditions like systemic sclerosis and other unmet medical needs. With a focus on novel therapies like tibulizumab (ZB-106) and torudokimab (ZB-880), Zura Bio aims to demonstrate their efficacy, safety, and dosing convenience. Despite a potentially overvalued stock, their strong balance sheet suggests they have the resources to advance their pipeline and potentially revolutionize treatment options for patients with these challenging conditions.
Resumo
Operações
Produtos e/ou serviços de Zura Bio Limited
- Drug Pipeline: This is the core of Zura Bio's activity. It likely consists of several drug candidates in various stages of development, targeting specific immune and inflammatory disorders.
- Lead Candidates: Zura Bio might have 2-3 drug candidates in the most advanced stages (potentially Phase 2 ready), like tibulizumab (ZB-106) and torudokimab (ZB-880).
- Technology Platform: They might have a proprietary technology platform for developing novel immunotherapies or other treatments relevant to their focus area.
- Intellectual Property: Patents and other intellectual property would be crucial to protect their discoveries and potential commercialization of successful drugs.
- Research Partnerships: Collaborations with academic institutions or other companies might be part of their strategy to accelerate drug development.
- Investor Relations: Publicly traded companies like Zura Bio need to maintain investor relations activities to raise capital and keep investors informed about their progress.
equipe executiva do Zura Bio Limited
- Sandeep Chidambar KulkarniCo-Founder, CEO & Director
- Kimberly Ann DavisCOO, Chief Legal Officer & Corporate Secretary
- Kiran NistalaChief Medical Officer & Head of Development
- Marlyn MathewVP of Finance & Accounting and Principal Financial & Accounting Officer
- Gary WhaleChief Technology Officer
- Theresa LowryChief Human Resources Officer
- Muzammil MustufaChief Business Officer
Principais indicadores financeiros
Resultados divulgados pela Zura Bio Limited , em USD.
- Cap. de mercado
- 409,2 mi
- Receita (TTM)
- 0
- P/L
- —
- LPA (diluído, TTM)
- -1.1
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 0 | -75,2 mi | -68,7 mi | |
| 0 | -55,2 mi | -52,4 mi | |
| 0 | -62,6 mi | -60,4 mi | |
| 0 | -27,2 mi | -25,7 mi |